Douglas Miehm
Stock Analyst at RBC Capital
(4.08)
# 1,710
Out of 5,032 analysts
412
Total ratings
51.9%
Success rate
5.7%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: APTX Apotex Health Corp. | Reiterated: Buy | $43.00 | $31.67 | +35.78% | 4 | Oct 6, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Reiterated: Buy | $21.00 → $22.00 | $18.22 | +20.75% | 43 | Sep 22, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $345 | $296.94 | +16.19% | 21 | Aug 9, 2026 | |
| AUPH Aurinia Pharmaceuticals | Reiterated: Hold | $15 → $16 | $15.69 | +1.98% | 44 | Aug 7, 2026 | |
| TSX: DR Medical Facilities Corporation | Reiterated: Hold | $19.00 | $15.00 | +26.67% | 47 | Aug 7, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Reiterated: Buy | $9.50 → $11.00 | $10.54 | +4.36% | 28 | Aug 7, 2026 | |
| MNKD MannKind | Reiterated: Hold | $4.75 | $3.71 | +28.03% | 10 | Aug 6, 2026 | |
| PCRX Pacira BioSciences | Reiterated: Hold | $24 → $25 | $24.76 | +0.97% | 6 | Aug 5, 2026 | |
| BLCO Bausch + Lomb | Reiterated: Buy | $21 | $17.18 | +22.24% | 38 | Jul 30, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Reiterated: Hold | $12.82 | $8.56 | +49.82% | 104 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.00 | $4.37 | +60.18% | 22 | May 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.72 | $15.12 | -48.94% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.45 → $3.5 | $0.598 | +485.28% | 30 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $19 | $3.78 | n/a | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 | €80.45 | n/a | 3 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $7.03 | n/a | 6 | Aug 4, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $2.3 | $0.000001 | n/a | 2 | Nov 6, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $8.70 | n/a | 1 | Feb 5, 2009 |
Apotex Health Corp.
Oct 6, 2026
Reiterated: Buy
Price Target: $43.00
Current: $31.67
Upside: +35.78%
DRI Healthcare Trust
Sep 22, 2026
Reiterated: Buy
Price Target: $21.00 → $22.00
Current: $18.22
Upside: +20.75%
Ligand Pharmaceuticals
Aug 9, 2026
Reiterated: Buy
Price Target: $345
Current: $296.94
Upside: +16.19%
Aurinia Pharmaceuticals
Aug 7, 2026
Reiterated: Hold
Price Target: $15 → $16
Current: $15.69
Upside: +1.98%
Medical Facilities Corporation
Aug 7, 2026
Reiterated: Hold
Price Target: $19.00
Current: $15.00
Upside: +26.67%
Knight Therapeutics Inc.
Aug 7, 2026
Reiterated: Buy
Price Target: $9.50 → $11.00
Current: $10.54
Upside: +4.36%
MannKind
Aug 6, 2026
Reiterated: Hold
Price Target: $4.75
Current: $3.71
Upside: +28.03%
Pacira BioSciences
Aug 5, 2026
Reiterated: Hold
Price Target: $24 → $25
Current: $24.76
Upside: +0.97%
Bausch + Lomb
Jul 30, 2026
Reiterated: Buy
Price Target: $21
Current: $17.18
Upside: +22.24%
Bausch Health Companies Inc.
Jul 30, 2026
Reiterated: Hold
Price Target: $12.82
Current: $8.56
Upside: +49.82%
May 10, 2026
Reiterated: Buy
Price Target: $7.00
Current: $4.37
Upside: +60.18%
Mar 19, 2026
Reiterated: Buy
Price Target: $7.72
Current: $15.12
Upside: -48.94%
Nov 19, 2025
Reiterated: Buy
Price Target: $2.45 → $3.5
Current: $0.598
Upside: +485.28%
Oct 8, 2021
Reiterated: Hold
Price Target: $18 → $19
Current: $3.78
Upside: n/a
Jun 23, 2021
Reiterated: Buy
Price Target: €22.00
Current: €80.45
Upside: n/a
Aug 4, 2016
Reiterated: Hold
Price Target: $1
Current: $7.03
Upside: n/a
Nov 6, 2013
Rated: Hold
Price Target: $3 → $2.3
Current: $0.000001
Upside: n/a
Feb 5, 2009
Upgraded: Buy
Price Target: n/a
Current: $8.70
Upside: n/a